Maria Rita Migliorino

Azienda Ospedaliera San Camillo-Forlanini — Italy

Medicine · Health Sciences

30h-index5.0kcitations79works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(61), Lung Cancer Research Studies(25), Cancer Immunotherapy and Biomarkers(24), Lung Cancer Diagnosis and Treatment(19), Colorectal Cancer Treatments and Studies(17)

Publications79 total

Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with <i>ALK</i> -positive non-small cell lung cancer
Future Science OA·2025Open Access
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results
Clinical Lung Cancer·2025Open Access
Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion
Current Oncology·2023· 4 citedOpen Access
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)
Journal of Thoracic Oncology·2022· 32 citedOpen Access
Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study
Pathologica·2022· 3 citedOpen Access
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
Journal of Thoracic Oncology·2022· 112 citedOpen Access
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
Journal of Hematology & Oncology·2022· 13 citedOpen Access
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients
Critical Reviews in Oncology/Hematology·2021· 13 citedOpen Access
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)
Lung Cancer·2021· 27 citedOpen Access
Phase II, noncomparative, open label, multicenter, study of osimertinib, in patients with locally advanced or metastatic EGFR mutated, T790M undetectable or unknown non-small cell lung cancer (Stage IIIB-IV) after no immediate prior EGFR TKI (OSIRIS study).
Journal of Clinical Oncology·2021· 2 cited
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy
European Journal of Cancer·2021· 36 citedOpen Access
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)
Journal for ImmunoTherapy of Cancer·2021· 24 citedOpen Access
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
Journal for ImmunoTherapy of Cancer·2021· 132 citedOpen Access
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
European Journal of Cancer·2021· 29 citedOpen Access
Smoking status during first‐line immunotherapy and chemotherapy in <scp>NSCLC</scp> patients: A case–control matched analysis from a large multicenter study
Thoracic Cancer·2021· 47 citedOpen Access
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
Drugs·2020· 116 citedOpen Access
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study
Lung Cancer·2020· 30 citedOpen Access
Target therapies nel tumore al polmone ALK-positivo: gestione del trattamento nei centri di oncologia del LazioIncontro di approfondimento e confronto sulla gestione dei pazienti e sulla strategia terapeutica nei carcinomi polmonari positivi al riarrangiamento di ALK.
Recenti Progressi in Medicina·2020Open Access
The Patient’s Perspective on Treatment with Dacomitinib: Patient-Reported Outcomes from the Phase III Trial ARCHER 1050
Future Oncology·2020· 3 citedOpen Access
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
Journal for ImmunoTherapy of Cancer·2020· 95 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Marcello Tiseo(18), Rita Chiari(16), Diego Cortinovis(16), Corrado Ficorella(15), Francesco Grossi(15), Filippo de Marinis(14), Alessio Cortellini(14), Rossana Berardi(14), Alain Gelibter(14), Raffaele Giusti(13), Federica Zoratto(13), Marco Filetti(13), Serena Ricciardi(12), Giampiero Porzio(12), Sebastiano Buti(11), Michele De Tursi(11), Francesca Mazzoni(11), Daniele Santini(10), Marco Russano(10), Katia Cannita(10)